99mTc 标记的褐藻糖胶(一种针对 P 选择素的 SPECT 示踪剂)的首次人体研究。

IF 3.1 3区 医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes, Didier Letourneur, Hein J Verberne, Cédric Chauvierre, Mia R Ståhle
{"title":"99mTc 标记的褐藻糖胶(一种针对 P 选择素的 SPECT 示踪剂)的首次人体研究。","authors":"Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes, Didier Letourneur, Hein J Verberne, Cédric Chauvierre, Mia R Ståhle","doi":"10.1186/s13550-024-01173-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of <sup>99m</sup>Tc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of <sup>99m</sup>Tc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of <sup>99m</sup>Tc-fucoidan (370 MBq). Moreover, <sup>99m</sup>Tc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to <sup>99m</sup>Tc-fucoidan SPECT/CT imaging.</p><p><strong>Results: </strong><sup>99m</sup>Tc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. <sup>99m</sup>Tc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT.</p><p><strong>Conclusions: </strong><sup>99m</sup>Tc-Fucoidan has a favorable biodistribution and safety profile. <sup>99m</sup>Tc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of <sup>99m</sup>Tc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium- 99m-labeled P-selectin tracer should be considered.</p><p><strong>Trial registration: </strong>Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"112"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576749/pdf/","citationCount":"0","resultStr":"{\"title\":\"First-in-human study of <sup>99m</sup>Tc-labeled fucoidan, a SPECT tracer targeting P-selectin.\",\"authors\":\"Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes, Didier Letourneur, Hein J Verberne, Cédric Chauvierre, Mia R Ståhle\",\"doi\":\"10.1186/s13550-024-01173-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of <sup>99m</sup>Tc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of <sup>99m</sup>Tc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of <sup>99m</sup>Tc-fucoidan (370 MBq). Moreover, <sup>99m</sup>Tc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to <sup>99m</sup>Tc-fucoidan SPECT/CT imaging.</p><p><strong>Results: </strong><sup>99m</sup>Tc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. <sup>99m</sup>Tc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT.</p><p><strong>Conclusions: </strong><sup>99m</sup>Tc-Fucoidan has a favorable biodistribution and safety profile. <sup>99m</sup>Tc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of <sup>99m</sup>Tc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium- 99m-labeled P-selectin tracer should be considered.</p><p><strong>Trial registration: </strong>Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.</p>\",\"PeriodicalId\":11611,\"journal\":{\"name\":\"EJNMMI Research\",\"volume\":\"14 1\",\"pages\":\"112\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576749/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJNMMI Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13550-024-01173-8\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJNMMI Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13550-024-01173-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

背景:动脉粥样硬化血栓形成过程中内皮细胞和血小板的活化以 P-选择素的上调为特征。因此,P-选择素是分子成像的潜在靶点,可用于早期识别血栓形成。褐藻糖胶是从褐藻中提取的一种多糖配体,对 P 选择素具有纳摩尔级的亲和力。这项首次人体研究在健康志愿者中评估了99m锝-褐藻糖胶的安全性、全身生物分布和剂量测定(良好生产规范级)。我们还研究了能否观察到 99mTc 褐藻糖胶与人体血栓的体内外结合。在静脉注射99m锝-褐藻糖胶(370 MBq)24小时后,我们对10名健康志愿者进行了共轭全身扫描。此外,还通过伽马计数法测量了体内外人体血栓(11人)对99m锝-褐藻糖胶的摄取量。此外,还对三名新确诊的深静脉血栓(DVT)患者进行了99m锝-褐藻糖胶SPECT/CT成像:所有参与者对99m锝-褐藻糖胶的耐受性良好,未出现任何与药物相关的不良反应。男性的全身吸收剂量与女性相当(0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq;p = 0.97)。伽马计数实验表明,用天然P-选择素配体Sialyl Lewis X阻断后,示踪剂与体外人体血栓的结合率降低了16%。在扫描的三名深静脉血栓患者中,有一人的血栓部位特异性吸收了99m锝-褐藻糖胶:结论:99m锝-褐藻糖胶具有良好的生物分布和安全性。结论:99m锝-褐藻糖胶具有良好的生物分布和安全性。99m锝-褐藻糖胶在体内和体外均表现出与人体血栓的特异性结合。尽管如此,体内实验结果并不支持将 99mTc 褐藻糖胶作为深静脉血栓成像模式进行进一步临床研究。应考虑在临床上使用锝-99m标记的P-选择素示踪剂:Clinicaltrials,NCT03422055.Registered 01/15/2018.URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739.Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin.

Background: Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of 99mTc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of 99mTc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of 99mTc-fucoidan (370 MBq). Moreover, 99mTc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to 99mTc-fucoidan SPECT/CT imaging.

Results: 99mTc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. 99mTc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT.

Conclusions: 99mTc-Fucoidan has a favorable biodistribution and safety profile. 99mTc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of 99mTc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium- 99m-labeled P-selectin tracer should be considered.

Trial registration: Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
EJNMMI Research
EJNMMI Research RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING&nb-
CiteScore
5.90
自引率
3.10%
发文量
72
审稿时长
13 weeks
期刊介绍: EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies. The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信